Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

USPTO Confirms Validity Of KCI NPWT Patents

Kinetic Concepts Inc. (KCI) has reported that the US Patent and Trademark Office (USPTO) issued office actions confirming the validity of three separate patents licensed to KCI by Wake Forest University Health Sciences in re-examination proceedings.

The patents associated with this decision include US Patent Nos. 5,636,643 (the ‘643 Patent), 5,645,081 (the ‘081 Patent), and 7,216,651 (the ‘651 Patent), which all relate to KCI’s negative pressure wound therapy technologies (NPWTs).

The USPTO has provided public notice of its intent to issue certificates of re-examination affirming the validity of key claims in the ‘643 Patent and the ‘081 Patent. The USPTO also issued a formal Office action confirming the validity of all claims in the ‘651 Patent.

“The advanced wound care market represents a very competitive environment,” said Stephen Seidel, KCI executive vice president, chief administrative officer and general counsel. “In a competitive market, patents remain important and are a protection due any company that truly innovates. KCI’s patents reflect thorough research undertaken with an eye towards patient care, meaningful clinical outcomes and reduced costs to the healthcare system. That’s what competition and innovation are all about.”